Table 2.
Predictive value of biomarkers for cancer treatments.
| Chemotherapy | Targeted therapy | Immunotherapy | Radiotherapy | |
|---|---|---|---|---|
| Tn/hs-Tn | +++ | + | +++ | ++ |
| BNP/NT-pro BNP | +++ | ++ | + | ++ |
| MPO | ++ | ++ | - | - |
| CRP/hs-CRP | ++ | ++ | ++ | + |
| ST2 | - | - | - | ++ |
| GDF-15 | + | + | - | + |
| PlGF | + | + | - | + |
| Galectin-3 | + | - | - | - |
| miRNAs | ++ | + | + | ++ |
| GPBB | + | - | - | - |
| Arginine-nitric oxide metabolites | + | + | - | - |
| Immune response proteins | + | - | - | - |
| Lipopolysaccharide-binding protein | - | - | - | + |
(−) Indicates that there is currently no research report on the relationship between biomarkers and cancer treatments. (+) Indicates that biomarkers have been reported to be associated with cancer treatment. (++) Represents a large number of studies reported an association between biomarkers and cancer treatment. (+++) Represents that biomarkers are recognized as predictors of cancer treatment.